These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25724786)

  • 1. Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.
    Calhoun G; Wang L; Almeida LE; Kenyon N; Afsar N; Nouraie M; Finkel JC; Quezado ZM
    Eur J Pharmacol; 2015 May; 754():125-33. PubMed ID: 25724786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.
    Sheehy KA; Finkel JC; Darbari DS; Guerrera MF; Quezado ZM
    Pain Pract; 2015 Nov; 15(8):E90-7. PubMed ID: 26205912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle cell disease in mice is associated with sensitization of sensory nerve fibers.
    Kenyon N; Wang L; Spornick N; Khaibullina A; Almeida LE; Cheng Y; Wang J; Guptill V; Finkel JC; Quezado ZM
    Exp Biol Med (Maywood); 2015 Jan; 240(1):87-98. PubMed ID: 25070860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
    Neri CM; Pestieau SR; Darbari DS
    Paediatr Anaesth; 2013 Aug; 23(8):684-9. PubMed ID: 23565738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis of Pain Behaviours in Humanized Mouse Models of Sickle Cell Anemia.
    Lei J; Benson B; Tran H; Ofori-Acquah SF; Gupta K
    PLoS One; 2016; 11(8):e0160608. PubMed ID: 27494522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
    Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
    J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexmedetomidine: pediatric pharmacology, clinical uses and safety.
    Su F; Hammer GB
    Expert Opin Drug Saf; 2011 Jan; 10(1):55-66. PubMed ID: 20718689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Models of Pain in Sickle Cell Disease.
    Sagi V; Song-Naba WL; Benson BA; Joshi SS; Gupta K
    Curr Protoc Neurosci; 2018 Oct; 85(1):e54. PubMed ID: 30265442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Dexmedetomidine in Pediatric Palliative Care: A Preliminary Study.
    Burns J; Jackson K; Sheehy KA; Finkel JC; Quezado ZM
    J Palliat Med; 2017 Jul; 20(7):779-783. PubMed ID: 28186850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of modulation of the alpha-2 receptor in tetrahydropalmatine (THP) analgesia in male Sprague-Dawley rats.
    Bruce W; Fonder H; Compton J; Garrett N
    J Diet Suppl; 2009; 6(1):13-21. PubMed ID: 22435350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
    Sezer Z; Sezer G; Tekol Y
    Neuro Endocrinol Lett; 2011; 32(4):552-6. PubMed ID: 21876510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.
    Cataldo G; Lunzer MM; Olson JK; Akgün E; Belcher JD; Vercellotti GM; Portoghese PS; Simone DA
    Pain; 2018 Jul; 159(7):1382-1391. PubMed ID: 29578946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alpha-2 adrenoreceptor agonists in anaesthesia and intensive care medicine].
    Mavropoulos G; Minguet G; Brichant JF
    Rev Med Liege; 2014 Feb; 69(2):97-101. PubMed ID: 24683831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids.
    Kohli DR; Li Y; Khasabov SG; Gupta P; Kehl LJ; Ericson ME; Nguyen J; Gupta V; Hebbel RP; Simone DA; Gupta K
    Blood; 2010 Jul; 116(3):456-65. PubMed ID: 20304807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of opioid use in sickle cell disease.
    Han J; Zhou J; Saraf SL; Gordeuk VR; Calip GS
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):479-486. PubMed ID: 28815799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness.
    Cain DM; Vang D; Simone DA; Hebbel RP; Gupta K
    Br J Haematol; 2012 Feb; 156(4):535-44. PubMed ID: 22171826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dexmedetomidine hydrochloride (Precedex), a new sedative in intensive care, its pharmacological characteristics and clinical study result].
    Taiji K
    Nihon Yakurigaku Zasshi; 2004 Sep; 124(3):171-9. PubMed ID: 15333990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice.
    Khaibullina A; Almeida LE; Wang L; Kamimura S; Wong EC; Nouraie M; Maric I; Albani S; Finkel J; Quezado ZM
    Blood Cells Mol Dis; 2015 Dec; 55(4):363-72. PubMed ID: 26460261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic uses for an alpha2 adrenergic receptor agonist--dexmedetomidine in pain management.
    Zhang X; Bai X
    Neurosci Lett; 2014 Feb; 561():7-12. PubMed ID: 24373989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.